Tetradecylacetate

Tetradecylacetate

SCHEMBL466058

CC(O)CO.CCCCCCCCCCCCCCOC(C)=O.CCOCC

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Tetradecylacetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
TSHR P16473 3/20 0.47
USP2 O75604 1/20 0.45
NAAA Q02083 1/20 0.44
CES2 O00748 1/20 0.43
MAPT P10636 1/20 0.42
EPHX1 P07099 1/20 0.42
PLA2G2C Q5R387 1/20 0.42
KDM4E B2RXH2 1/20 0.41
DUSP3 P51452 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hexyl Acetate SCHEMBL896029 1.00 ALDH1A1 (0.53) ALDH1A1TSHRUSP2NAAACES2
Acetic Acid Pentyl Ester SCHEMBL2269446 0.98 ALDH1A1 (0.55) ALDH1A1TSHRUSP2NAAACES2
Acetic Acid Butyl Ester SCHEMBL107642 0.93 ALDH1A1 (0.62) ALDH1A1TSHRUSP2MAPT
Tetradecylacetate SCHEMBL633019 0.93 ALDH1A1 (0.61) ALDH1A1TSHRUSP2NAAACES2
Octyl Acetate SCHEMBL27849660 0.93 ALDH1A1 (0.61) ALDH1A1TSHRUSP2NAAACES2
Acetic Acid Pentyl Ester SCHEMBL27685689 0.92 ALDH1A1 (0.63) ALDH1A1TSHRUSP2NAAAMAPT
Acetic Acid Pentyl Ester SCHEMBL27678839 0.89 ALDH1A1 (0.60) ALDH1A1TSHRUSP2NAAACES2
Dodecylacetate SCHEMBL353028 0.88 ALDH1A1 (0.68) ALDH1A1TSHRNAAACES2EPHX1
Decylacetate SCHEMBL3426391 0.88 ALDH1A1 (0.68) ALDH1A1TSHRNAAACES2EPHX1
Tetradecylacetate SCHEMBL537712 0.88 ALDH1A1 (0.68) ALDH1A1TSHRNAAACES2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 794 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250281376-A1 Hair Care Composition CORET JOEL MARCEL (US) 2025-09-11 US claimed
US-20250269034-A1 TOPICAL TETRACYCLINE COMPOSITIONS JOURNEY MEDICAL CORP (US) 2025-08-28 US claimed
CN-118948631-B Oil-in-water cleansing composition 深圳市护家科技有限公司 2025-02-14 CN claimed
CN-118948631-A Oil-in-water cleansing composition 深圳市护家科技有限公司 2024-11-15 CN claimed
US-12138311-B2 Topical tetracycline compositions JOURNEY MEDICAL CORPORATION (US) 2024-11-12 US claimed
CN-116370328-A Skin care composition and external skin preparation 深圳市护家科技有限公司 2023-07-04 CN claimed
US-10946101-B2 Surfactant-free water-free foamable compositions, breakable foams and gels and their uses VYNE THERAPEUTICS INC. (US) 2021-03-16 US claimed
US-20210015927-A1 SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES SWK FUNDING LLC 2021-01-21 US claimed
US-20200261586-A1 TOPICAL TETRACYCLINE COMPOSITIONS FOAMIX PHARMACEUTICALS LTD. (IL) 2020-08-20 US claimed
US-20190134204-A1 SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES SWK FUNDING LLC 2019-05-09 US claimed
WO-2011039637-A2 SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES FOAMIX LTD. (IL) 2011-04-07 WO claimed
WO-2011039638-A2 TOPICAL TETRACYCLINE COMPOSITIONS FOAMIX LTD. (IL) 2011-04-07 WO claimed
EP-2025058-A2 COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS Paloma Pharmaceuticals, Inc. (US) 2009-02-18 EP claimed
US-20080233067-A1 Method Of Making Enhanced Efficacy Antiperspirant Actives COLGATE-PALMOLIVE COMPANY (US) 2008-09-25 US claimed
WO-2007133249-A2 COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS PALOMA PHARMACEUTICALS, INC. (US) 2007-11-22 WO claimed
US-20060257337-A1 Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis PALOMA PHARMACEUTICALS, INC. 2006-11-16 US claimed
WO-2006062926-A1 METHODS FOR PREPARING SKIN FOR BIOMETRIC IMAGE ACQUISITION APRILIS, INC. (US) 2006-06-15 WO claimed
US-20040185018-A1 Nail enamelcompositions and methods CITICORP USA, INC. 2004-09-23 US claimed
US-5516506-A LOTIONS WITH GLYCERINE, MAGNESIUM ALUMINUM SILICATE, XANTHAN GUM, ISOSTEARIC ACID, SILICONES, OCTYL METHOXY CINNAMATE AND EMOLLIENTS AND ESTER COMPOUNDS BERNEL CHEMICAL CO. (US) 1996-05-14 US claimed
US-5008100-A Stable sunscreens ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) 1991-04-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040185018-A1 Nail enamelcompositions and methods ETF1, POLR1C, PIK3C3 ALDH1A1 639/4885TSHR 1642/4885USP2 1228/4885
US-20060257337-A1 Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis MKI67, VEGFA, TYR ALDH1A1 2351/4885TSHR 3927/4885USP2 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.